DOI.org (Crossref) , Respiratory Medicine , vol
Tirzepatide has a shorter track record simply because it is newer, approved for weight loss in the US in 2023
Experimental investigations have demonstrated that cholangiocytes are sensitive to GLP-1 and respond with augmented proliferation, potentially increasing the risk of duct obstruction [47,48]
The motivation is gone because it no longer induces the same reward it did, which I think the only way around that, if the person really needs the medication, is to have either external ways of being motivated, such as having a trainer who goes, Get out there and do your lifting, or, enough internal sense of, I need to do this because it's good for me, not because it feels good anymore. Which is a very difficult position
Soric MM, Moorman JM, Boyle JA, Dengler-Crish CM